Esperion Therapeutics ESPR Non-cash interest expense related to the royalty sale liability
Non-cash interest expense related to the royalty sale liability at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:NonCashInterestExpenseRelatedToRoyaltySaleLiability.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's non-cash interest expense related to the royalty sale liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's non-cash interest expense related to the royalty sale liability?
- Esperion Therapeutics (ESPR) reported non-cash interest expense related to the royalty sale liability of $13.89M in Q1 2026.
- How has Esperion Therapeutics's non-cash interest expense related to the royalty sale liability changed year-over-year?
- Esperion Therapeutics's non-cash interest expense related to the royalty sale liability increased by 6.1% year-over-year, from $13.09M to $13.89M.
- What does non-cash interest expense related to the royalty sale liability mean?
- This represents the non-cash interest expense associated with liabilities created from the sale of future royalty rights. It reflects the effective interest rate applied to the royalty liability balance as it is amortized over time. This adjustment is necessary to reconcile net income with cash flow from operations by removing non-cash financing costs.